Small Stocks, Big Money™

Alta Global Group (NYSE American: MMA) is rolling out "Hype," a mobile marketing platform designed for combat sports gyms, coaches, and athlete influencers. Targeting 45,000 gyms across the U.S., Hype offers subscription plans from $39 to $299 per month, plus a 5% transaction fee. The platform allows users to create mobile-optimized websites, manage payments, and engage followers through email and text marketing. Initial rollout focuses on California and Texas, with nationwide expansion planned for 2024-2025. Hype aims to revolutionize gym marketing by converting social media followers into dedicated gym members, driving recurring revenue and community engagement.

American Resources Corporation's (Nasdaq: AREC) subsidiary, ReElement Technologies, has successfully separated and purified rare earth elements from ore feedstock to achieve over 99.5% purity. Notably, the company produced 99.7% pure Neodymium and 99.9% pure Neodymium/Praseodymium. Utilizing its innovative Ligand Assisted Displacement (LAD) chromatography, ReElement offers an environmentally friendly and cost-effective alternative to traditional solvent extraction methods. The company is expanding its capabilities, focusing on both recycled magnets and rare earth ores, with plans to scale production in Marion, Indiana, leveraging its efficient, modular technology. This achievement positions ReElement as a key player in the global rare earth market, projected to reach $14.24 billion by 2030.

Greenwich LifeSciences (Nasdaq: GLSI) has announced the expansion of its Phase III FLAMINGO-01 clinical trial, evaluating the GLSI-100 immunotherapy for preventing breast cancer recurrences, into Spain. Partnering with GEICAM, the leading academic breast cancer research network in Spain, the trial now includes 38 hospitals, with 30 having conducted site initiation visits and 19 sites activated. This expansion has nearly doubled the number of sites from the U.S., reflecting significant progress and collaboration. The study aims to enroll patients with HER2-positive breast cancer across up to 150 sites globally, including further locations in Europe.

Trinity Biotech (Nasdaq: TRIB) reported preliminary Q2 2024 revenues of $15.5-$16.0 million, showcasing significant year-over-year growth from $13.9 million in Q2 2023. The company has also entered into a UK distribution agreement with MedScience, effective August 1, 2024, covering clinical chemistry, infectious disease, and autoimmune products. CEO John Gillard attributes the robust revenue growth to the success of their new HIV screening product, TrinScreen HIV, and expects to continue expanding their market presence. Trinity Biotech maintains its financial guidance, aiming for $20 million in annualized run-rate EBITDASO and $75 million in revenues by Q2 2025.